Published in Vaccine Weekly, November 15th, 2006
In this study involving 52 children between 6-35 months of age, CAIV-T prompted significantly higher seroconversion rates and higher antibody titers than TIV. CAIV-T also demonstrated significantly more cross-reactivity to the mismatched strain that predominantly circulated during the 2004-2005 season. The results were...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly